Continuous infusion of recombinant activated factor VII for bleeding control after lobectomy in a patient with inherited factor VII deficiency.

Inherited factor VII (FVII) deficiency is a rare recessive inherited coagulation disorder with limited available information, especially in patients undergoing major thoracic surgery. In addition, an optimal management strategy for the disease has not been defined. We herein report a case involving a 61-year-old man with asymptomatic FVII deficiency who underwent a right middle and lower lobectomy to treat lung cancer.

Properties of a recombinant bovine tissue factor expressed by Silkworm pupae and its performance as an Owren-type prothrombin time reagent for warfarin monitoring.

Tissue factor (TF), or thromboplastin, is a glycoprotein that triggers the extrinsic coagulation pathway. In blood coagulation testing, TF has been used as a natural source for determining Quick prothrombin time (PT) or the Owren PT (OBT). Currently, natural sources are being replaced with recombinant proteins because of their uniform characteristics and the possibility of stable mass production of PT reagents.

[The expression of recombinant factor VII variants is influenced by different cells for transfection using expression studies].

To investigate the influence of different transfected cells using expression studies of dysfunctional factor VII variants, we expressed recombinant FVII using COS-1 cells, CHO-K1 cells, BHK cells and HEK293 cells. The mutant type F7 DNAs with Leu-48Pro in the prepeptide domain, with Ser126Phe in the EGF-2 domain and with Gly354Cys in the catalytic domain were transfected in the four kinds of cell lines. Additionally, FVII Ser126Tyr and Ser126Gly were expressed to investigate different substitutions from Phe in position 126 in FVII.

Factor VII deficiency due to compound heterozygosity for Leu-48Pro mutation and a novel Pro260Leu mutation.

We investigated the mechanisms responsible for factor VII (FVII) deficiency in a compound heterozygous Japanese patient with mutations both in the signal peptide and in the catalytic domain. FVII activity (FVII:C) and antigen (FVII:Ag) levels of the patient were 14.5% and 12.